血清Gal-1、GPX3、TGAb、TPOAb变化及其与甲状腺癌病情严重程度的相关性

Changes of serum Gal-1,GPX3,TGAb,TPOAb and their correlation with the severity of thyroid cancer

目的探讨甲状腺癌血清半乳糖凝集素-1(Gal-1)、谷胱甘肽过氧化物酶3(GPX3)、甲状腺球蛋白抗体(TGAb)、甲状腺过氧化物酶抗体(TPOAb)变化及其与病情严重程度的相关性。方法前瞻性选择2022年6月至2024年6月南阳市中心医院收治的108例甲状腺癌患者作为观察组纳入研究,其中轻度组55例和中重度组53例,选取同期本院100例甲状腺良性病患者作为对照组。比较观察组和对照组患者以及观察组中不同病情严重程度患者的血清Gal-1、GPX3、TGAb、TPOAb水平,并采用Pearson相关分析法分析甲状腺癌血清Gal-1、GPX3、TGAb、TPOAb水平与病情严重程度的相关性。结果观察组患者的血清Gal-1、TGAb、TPOAb水平分别为(221.49±33.01)ng/mL、(132.58±15.40)IU/mL、(50.11±5.70)IU/mL,明显高于对照组的(87.15±10.70)ng/mL、(61.97±8.16)IU/mL、(23.80±4.19)IU/mL,GPX3水平为(74.28±8.63)IU/mL,明显低于对照组的(155.45±20.29)IU/mL,差异均有统计学意义(P<0.05);中重度组患者的血清Gal-1、TGAb、TPOAb水平分别为(240.68±45.02)ng/mL、(155.45±20.95)IU/mL、(65.68±7.02)IU/mL,明显高于轻度组的(202.14±42.14)ng/mL、(130.38±14.36)IU/mL、(45.14±3.14)IU/mL,GPX3水平为(62.04±7.90)μg/L,明显低于轻度组的(95.48±10.03)μg/L,差异均有统计学意义(P<0.05);Pearson相关分析结果显示,血清Gal-1、TGAb、TPOAb水平与病情严重程度均呈正相关(r=0.762、0.754、0.825,P<0.05),GPX3水平与病情严重程度呈负相关(r=-0.610,P<0.05)。结论血清Gal-1、TGAb、TPOAb水平在甲状腺癌患者中表达明显升高,GPX3水平明显降低,检测血清Gal-1、GPX3、TGAb、TPOAb水平有助于评估甲状腺癌患者的病情程度,为临床治疗提供参考。

Objective To investigate the changes of serum galactin-1(Gal-1),glutathione peroxidase 3(GPX3),thyroglobulin antibody(TGAb),and thyroid peroxidase antibody(TPOAb)in thyroid cancer,and their correla-tion with the severity of the disease.Methods A total of 108 patients with thyroid cancer admitted to Nanyang Central Hospital from June 2022 to June 2024 were prospectively selected as the observation group,including 55 cases in the mild subgroup and 53 cases in the moderate and severe subgroup.During the same period,100 cases of benign thyroid disease in the hospital were selected as the control group.Serum levels of Gal-1,GPX3,TGAb,and TPOAb were com-pared between the observation group and the control group and between patients with different severity of disease.Pear-son correlation analysis was used to analyze their correlation between the changes of serum Gal-1,GPX3,TGAb,TPOAb and the severity of thyroid cancer.Results The serum Gal-1,TGAb,and TPOAb levels of patients in the ob-servation group were(221.49±33.01)ng/mL,(132.58±15.40)IU/mL,and(50.11±5.70)IU/mL,which were significantly higher than(87.15±10.70)ng/mL,(61.97±8.16)IU/mL,(23.80±4.19)IU/mL of the control group;the GPX3 level was(74.28±8.63)IU/mL,which was significantly lower than(155.45±20.29)IU/mL in the control group;the differences were statistically significant(P<0.05).The serum Gal-1,TGAb,and TPOAb levels in the moderate and severe subgroup were(240.68±45.02)ng/mL,(155.45±20.95)IU/mL,and(65.68±7.02)IU/mL,which were significantly higher than(202.14±42.14)ng/mL,(130.38±14.36)IU/mL,and(45.14±3.14)IU/mL in the mild subgroup;the GPX3 level was(62.04±7.90)μg/L,which was significantly lower than(95.48±10.03)μg/L in the mild subgroup;the differences were statistically significant(P<0.05).Pearson correlation analysis showed that serum Gal-1,TGAb,and TPOAb levels were positively correlated with the severity of the disease(r=0.762,0.754,0.825,P<0.05),and that GPX3 levels were nega-tively correlated with the severity of the disease(r=-0.610,P<0.05).Conclusion Serum Gal-1,TGAb,and TPOAb levels are significantly increased in patients with thyroid cancer,while GPX3 levels are significantly decreased.Detec-tion of serum Gal-1,GPX3,TGAb,and TPOAb is helpful to evaluate the severity of thyroid cancer and provides refer-ences for clinical treatment.